ISIS Pharmaceuticals, Inc. Stock Nasdaq
Stocks
US4643301090
Biotechnology & Medical Research
| Market Cap | 8.6B 7.48B 6.96B 6.39B 12.07B 821B 12.26B 82.06B 32.2B 409B 32.31B 31.6B 1,371B | P/E 2026 * |
-14.6x | P/E 2027 * | -28.3x |
|---|---|---|---|---|---|
| Enterprise Value | 8.21B 7.14B 6.64B 6.1B 11.51B 784B 11.69B 78.28B 30.72B 390B 30.83B 30.15B 1,308B | EV / Sales 2026 * |
8.9x | EV / Sales 2027 * | 5.97x |
| Free-Float |
99.09% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: ISIS Pharmaceuticals, Inc.
| 1 day | +1.33% |
| Manager | Title | Age | Since |
|---|---|---|---|
D. Walke
IRC | Investor Relations Contact | 60 | 01/07/2012 |
Brett Monia
CEO | Chief Executive Officer | 64 | 01/01/2020 |
Elizabeth Hougen
DFI | Director of Finance/CFO | 64 | 01/05/2000 |
| Director | Title | Age | Since |
|---|---|---|---|
Joseph Klein
BRD | Director/Board Member | 64 | 13/12/2005 |
| Director/Board Member | 73 | 01/05/2002 | |
Brett Monia
BRD | Director/Board Member | 64 | 25/03/2019 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.33% | +2.73% | - | - | 8.6B | |
| -1.40% | +2.59% | -1.71% | +11.28% | 48.53B | |
| -2.41% | -0.90% | +411.96% | +495.33% | 39.87B | |
| -1.16% | +12.96% | +28.81% | +7.25% | 38.68B | |
| -1.88% | -3.03% | +5.69% | +53.00% | 35.13B | |
| -1.74% | +5.12% | +14.44% | +41.77% | 29.79B | |
| -0.21% | -4.04% | +36.40% | +125.75% | 16.11B | |
| -2.85% | -3.92% | - | - | 16.08B | |
| -0.64% | +2.65% | +3.40% | +13.11% | 13.61B | |
| -1.19% | -1.32% | -1.73% | -34.37% | 12.62B | |
| Average | -1.22% | +1.05% | +62.16% | +89.14% | 27.82B | |
| Weighted average by Cap. | -1.50% | +2.03% | +79.78% | +108.61% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 922M 802M 746M 685M 1.29B 88.04B 1.31B 8.8B 3.45B 43.83B 3.46B 3.39B 147B | 1.4B 1.22B 1.13B 1.04B 1.97B 134B 2B 13.37B 5.25B 66.61B 5.26B 5.15B 223B |
| Net income | -589M -512M -477M -438M -827M -56.26B -840M -5.62B -2.21B -28.01B -2.21B -2.16B -93.93B | -317M -275M -256M -235M -444M -30.23B -451M -3.02B -1.19B -15.05B -1.19B -1.16B -50.46B |
| Net Debt | -396M -344M -320M -294M -555M -37.76B -564M -3.77B -1.48B -18.8B -1.49B -1.45B -63.03B | -241M -209M -195M -179M -338M -22.97B -343M -2.3B -901M -11.44B -904M -884M -38.35B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
